Predictive Factors for Submacular Hemorrhage in Age-related Macular Degeneration: A Retrospective Study.

Autor:	Moon H; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea., Kang HG; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea., Lee J; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea., Lee CS; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea., Kim M; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea., Byeon SH; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea., Kim SS; Department of Ophthalmology, Institute of Vision Research, Severance Eye Hospital, Yonsei University College of Medicine, Seoul, Korea.
Jazyk:	angličtina
Zdroj:	Korean journal of ophthalmology : KJO [Korean J Ophthalmol] 2024 Dec; Vol. 38 (6), pp. 471-479. Date of Electronic Publication: 2024 Oct 22.
DOI:	10.3341/kjo.2024.0032
Abstrakt:	Purpose: Little is known about the major risk factors for submacular hemorrhage (SMH). This study aimed to evaluate the factors associated with SMH in patients with neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy receiving three consecutive loading doses of intravitreal aflibercept or ranibizumab injections. Methods: This retrospective cross-sectional study included 48 patients diagnosed with nAMD and polypoidal choroidal vasculopathy who completed three loading doses under a treat-and-extend regimen. Patients were divided into the SMH group and the non-SMH group (age- and sex-matched without SMH), with 24 patients in each group. Intravitreal injections, agents, and optical coherence tomography (OCT) features were compared. Results: In the SMH group, SMH occurred approximately 3.29 years after post-nAMD diagnosis. The non-SMH group received more intravitreal injections of aflibercept and brolucizumab during the follow-up period after the initial loading phase. The SMH group exhibited a higher prevalence of serous/hemorrhagic pigment epithelial detachments (PEDs) at the last visit before SMH occurrence compared to the non-SMH group. Patients with a PED increase in the past two visits showed a higher tendency in the SMH group. No other OCT features significantly correlated with SMH development. Conclusions: The presence of serous/hemorrhagic PEDs may indicate a higher risk of SMH, and eyes with these features should be closely monitored to prevent sudden and devastating visual loss caused by SMH.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu